227 related articles for article (PubMed ID: 30473464)
21. Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.
Fukushima H; Kataoka M; Nakanishi Y; Sakamoto K; Takemura K; Suzuki H; Ito M; Tobisu KI; Fujii Y; Koga F
Urol Oncol; 2018 Apr; 36(4):156.e9-156.e16. PubMed ID: 29051030
[TBL] [Abstract][Full Text] [Related]
22. Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic Cancer.
Usón Junior PLS; Rother ET; Maluf FC; Bugano DDG
Clin Colorectal Cancer; 2018 Sep; 17(3):187-197. PubMed ID: 29615310
[TBL] [Abstract][Full Text] [Related]
23. Body composition measurements and clinical outcomes in patients with resectable pancreatic adenocarcinoma - analysis from SWOG S1505.
Sohal DPS; Boutin RD; Lenchik L; Kim J; Beg MS; Wang-Gillam A; Wade JL; Guthrie KA; Chiorean EG; Ahmad SA; Lowy AM; Philip PA; Chang VT
J Gastrointest Surg; 2024 Mar; 28(3):232-235. PubMed ID: 38445914
[TBL] [Abstract][Full Text] [Related]
24. Comparing Western and Eastern criteria for sarcopenia and their association with survival in patients with pancreatic cancer.
Wu CH; Chang MC; Lyadov VK; Liang PC; Chen CM; Shih TT; Chang YT
Clin Nutr; 2019 Apr; 38(2):862-869. PubMed ID: 29503056
[TBL] [Abstract][Full Text] [Related]
25. Impact of Sarcopenia on Survival in Patients Treated with FOLFIRINOX in a First-Line Setting for Metastatic Pancreatic Carcinoma.
Lellouche L; Barat M; Pellat A; Leroux J; Corre F; Hallit R; Assaf A; Brezault C; Dhooge M; Soyer P; Coriat R
J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983212
[TBL] [Abstract][Full Text] [Related]
26. Skeletal Muscle Attenuation (Sarcopenia) Predicts Reduced Overall Survival in Patients with Advanced Epithelial Ovarian Cancer Undergoing Primary Debulking Surgery.
Ataseven B; Luengo TG; du Bois A; Waltering KU; Traut A; Heitz F; Alesina PF; Prader S; Meier B; Schneider S; Koch JA; Walz M; Groeben HT; Nina P; Brunkhorst V; Heikaus S; Harter P
Ann Surg Oncol; 2018 Oct; 25(11):3372-3379. PubMed ID: 30069659
[TBL] [Abstract][Full Text] [Related]
27. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma.
Rollins KE; Tewari N; Ackner A; Awwad A; Madhusudan S; Macdonald IA; Fearon KC; Lobo DN
Clin Nutr; 2016 Oct; 35(5):1103-9. PubMed ID: 26411749
[TBL] [Abstract][Full Text] [Related]
28. Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients.
Shin DW; Kim MA; Lee JC; Kim J; Hwang JH
BMC Res Notes; 2021 Jul; 14(1):272. PubMed ID: 34266478
[TBL] [Abstract][Full Text] [Related]
29. Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy.
Guion-Dusserre JF; Bertaut A; Ghiringhelli F; Vincent J; Quipourt V; Marilier S; Tharin Z; Bengrine-Lefevre L
World J Gastroenterol; 2016 Nov; 22(42):9378-9386. PubMed ID: 27895425
[TBL] [Abstract][Full Text] [Related]
30. The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients.
Basile D; Parnofiello A; Vitale MG; Cortiula F; Gerratana L; Fanotto V; Lisanti C; Pelizzari G; Ongaro E; Bartoletti M; Garattini SK; Andreotti VJ; Bacco A; Iacono D; Bonotto M; Casagrande M; Ermacora P; Puglisi F; Pella N; Fasola G; Aprile G; Cardellino GG
J Cachexia Sarcopenia Muscle; 2019 Apr; 10(2):368-377. PubMed ID: 30719874
[TBL] [Abstract][Full Text] [Related]
31. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
[TBL] [Abstract][Full Text] [Related]
32. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
[TBL] [Abstract][Full Text] [Related]
33. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
Stein SM; James ES; Deng Y; Cong X; Kortmansky JS; Li J; Staugaard C; Indukala D; Boustani AM; Patel V; Cha CH; Salem RR; Chang B; Hochster HS; Lacy J
Br J Cancer; 2016 Mar; 114(7):737-43. PubMed ID: 27022826
[TBL] [Abstract][Full Text] [Related]
34. Sarcopenia as a Predictor of Survival in Patients with Pancreatic Adenocarcinoma After Pancreatectomy.
Rom H; Tamir S; Van Vugt JLA; Berger Y; Perl G; Morgenstern S; Tovar A; Brenner B; Benchimol D; Kashtan H; Sadot E
Ann Surg Oncol; 2022 Mar; 29(3):1553-1563. PubMed ID: 34716836
[TBL] [Abstract][Full Text] [Related]
35. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.
Hohla F; Hopfinger G; Romeder F; Rinnerthaler G; Bezan A; Stättner S; Hauser-Kronberger C; Ulmer H; Greil R
Int J Oncol; 2014 Jan; 44(1):319-26. PubMed ID: 24247204
[TBL] [Abstract][Full Text] [Related]
36. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.
Cushen SJ; Power DG; Murphy KP; McDermott R; Griffin BT; Lim M; Daly L; MacEneaney P; O' Sullivan K; Prado CM; Ryan AM
Clin Nutr ESPEN; 2016 Jun; 13():e39-e45. PubMed ID: 28531567
[TBL] [Abstract][Full Text] [Related]
37. Resectable pancreatic adenocarcinomas: will neoadjuvant FOLFIRINOX replace upfront surgery in the standard of care?
Antonios A; Gharios J; Tohme C
Future Oncol; 2017 May; 13(11):951-953. PubMed ID: 28481149
[No Abstract] [Full Text] [Related]
38. Impact of sarcopenia on survival of pancreatic cancer patients treated with concurrent chemoradiotherapy.
Cho WK; Yu JI; Park HC; Lim DH; Kim TH; Chie EK
Tumori; 2021 Jun; 107(3):247-253. PubMed ID: 32646298
[TBL] [Abstract][Full Text] [Related]
39. The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy.
Takeda T; Sasaki T; Suzumori C; Mie T; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Int J Clin Oncol; 2021 Jul; 26(7):1293-1303. PubMed ID: 33791917
[TBL] [Abstract][Full Text] [Related]
40. Sarcopenia as a prognostic biomarker of advanced urothelial carcinoma.
Fukushima H; Yokoyama M; Nakanishi Y; Tobisu K; Koga F
PLoS One; 2015; 10(1):e0115895. PubMed ID: 25612215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]